JMP Securities upgraded shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) from a market perform rating to an outperform rating in a report published on Thursday, Marketbeat Ratings reports. JMP Securities currently has $33.00 price target on the stock.

Other analysts have also recently issued reports about the company. Oppenheimer Holdings, Inc. set a $28.00 price target on Syros Pharmaceuticals and gave the stock a buy rating in a research report on Monday, June 12th. Cann restated a buy rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a report on Monday, August 21st. Cowen and Company restated a buy rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research cut Syros Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded Syros Pharmaceuticals from a sell rating to a hold rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Syros Pharmaceuticals has an average rating of Buy and a consensus target price of $24.64.

Shares of Syros Pharmaceuticals (SYRS) traded down 3.29% during mid-day trading on Thursday, reaching $14.72. The company had a trading volume of 273,558 shares. The stock’s 50-day moving average price is $16.38 and its 200 day moving average price is $16.38. Syros Pharmaceuticals has a 1-year low of $10.22 and a 1-year high of $17.89. The company’s market capitalization is $386.55 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities analysts expect that Syros Pharmaceuticals will post ($2.09) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/syros-pharmaceuticals-inc-syrs-upgraded-at-jmp-securities/1601003.html.

In other Syros Pharmaceuticals news, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total value of $273,125.00. Following the completion of the sale, the insider now directly owns 12,500 shares in the company, valued at approximately $273,125. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the completion of the sale, the director now owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,564 shares of company stock valued at $476,803.

A number of large investors have recently modified their holdings of SYRS. Wells Fargo & Company MN purchased a new stake in Syros Pharmaceuticals in the 1st quarter valued at $225,000. Bank of New York Mellon Corp purchased a new position in shares of Syros Pharmaceuticals during the 1st quarter worth $185,000. Redmile Group LLC grew its holdings in shares of Syros Pharmaceuticals by 0.5% during the 1st quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock worth $15,177,000 after purchasing an additional 4,300 shares during the period. Schwab Charles Investment Management Inc. purchased a new position in shares of Syros Pharmaceuticals during the 2nd quarter worth $343,000. Finally, Rhumbline Advisers purchased a new position in shares of Syros Pharmaceuticals during the 2nd quarter worth $198,000. Institutional investors own 59.61% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.